Core Insights - The report from Southwest Securities indicates that first-line treatment for driver gene-negative NSCLC (non-small cell lung cancer) patients primarily relies on PD(L)-1 ± chemotherapy, with projected market sizes for immune drugs in this segment reaching approximately 7.5 billion yuan in China and 18 billion yuan in the U.S. by 2030 [1] Group 1: Market Overview - The driver gene-negative segment accounts for 31% of newly diagnosed NSCLC patients in both China and the U.S. [1] - The projected market size for immune drugs used in first-line treatment of driver gene-negative NSCLC is estimated to be around 7.5 billion yuan in China and 18 billion yuan in the U.S. by 2030 [1] Group 2: Next-Generation Immunotherapy - Next-generation immunotherapy options for NSCLC are advancing, including bispecific antibodies and IO+ADC (immuno-oncology plus antibody-drug conjugates) [2] - Current PD(L)-1 drugs, such as Pembrolizumab and Atezolizumab, have established their clinical position but face limitations in long-term efficacy, particularly in patients with low PD-L1 expression [2] Group 3: Bispecific Antibody Treatment - Bispecific antibodies can bind to two antigens or epitopes, balancing safety and efficacy, with the approval of Ivorisumab in 2024 expected to stimulate interest in PD-(L)1/VEGF therapies [3] - The clinical data and technological pathways for bispecific antibodies are gaining recognition, with the potential for tri-specific antibodies to become a new trend in immuno-oncology treatment [3] Group 4: IO+ADC Treatment - ADCs combine cytotoxic drugs with monoclonal antibodies targeting tumors, offering precise delivery and effective treatment with lower toxicity [3] - Clinical results for TROP2 ADC combined with K-drug show comparable ORR and PFS data to K-drug plus chemotherapy, providing new solutions for patients intolerant to chemotherapy [3]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The proportion of driver gene-negative non-small cell lung cancer (NSCLC) patients is approximately 31% in both China and the United States, indicating a significant market opportunity for treatments targeting this demographic [2][15] - The estimated market size for immune drugs used in first-line treatment of driver gene-negative NSCLC is projected to be around 7.5 billion CNY (approximately 1.1 billion USD) in China and 18 billion CNY (approximately 2.7 billion USD) in the United States by 2030 [2] - The current first-line treatment for advanced driver gene-negative NSCLC primarily relies on PD(L)-1 inhibitors combined with chemotherapy, but there are limitations in long-term efficacy and options for patients intolerant to chemotherapy [3] Summary by Sections Section 1: NSCLC Global Overview - Lung cancer is the leading cancer type globally, with new cases accounting for approximately 12% of all cancer cases in 2022, translating to about 2.5 million new lung cancer cases [10] - In China, lung cancer represents about 22% of new cancer cases, with approximately 1.06 million new cases in 2022 [10] Section 2: Market Potential for Driver Gene-Negative NSCLC - The report highlights the significant market potential for immune therapies in treating driver gene-negative NSCLC, with a focus on the limitations of current treatment options [2][3] Section 3: Next-Generation Immunotherapy Approaches - The report discusses the advancements in dual (multi) antibody therapies and immune-oncology (IO) combined with antibody-drug conjugates (ADC), emphasizing their potential to improve treatment outcomes for patients with driver gene-negative NSCLC [5][8] - The clinical data supporting these new therapies is expected to catalyze further investment and development in this area [5] Section 4: Treatment Guidelines Comparison - The report compares treatment guidelines for driver gene-negative NSCLC between the United States and China, noting differences in treatment stratification and recommended therapies [32][34] - The U.S. guidelines emphasize PD-L1 expression levels, while Chinese guidelines focus more on performance status (PS) [32][34] Section 5: Future Catalysts - Key upcoming clinical data releases and studies are highlighted as potential catalysts for investment opportunities in the sector, particularly regarding dual antibodies and ADC therapies [5][8]